Displaying drugs 926 - 950 of 976 in total
10-(4-Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione
Experimental
Matched Name: … Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene …
Imatinib
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ... [L42220]
Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Benzamides and benzamide derivatives …
Matched Products: … IMATINIB AMAROX 100MG FTA ... IMATINIB AMAROX 400MG FTA …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Benzamides and benzamide derivatives …
Matched Products: … IMATINIB AMAROX 100MG FTA ... IMATINIB AMAROX 400MG FTA …
Adagrasib
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate...
Approved
Investigational
Matched Synonyms: … 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl …
Matched Description: … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations ... of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and ... Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Description: … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations ... of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and ... Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Vorapaxar
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Approved
Matched Synonyms: … 9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate ... fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate …
Matched Iupac: … [(1E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-dodecahydronaphtho[2,3-c]furan-6-yl]carbamate …
Matched Categories: … Blood and Blood Forming Organs …
Matched Iupac: … [(1E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-dodecahydronaphtho[2,3-c]furan-6-yl]carbamate …
Matched Categories: … Blood and Blood Forming Organs …
3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid
Experimental
Matched Name: … 3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic …
Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate
Experimental
Matched Name: … Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate …
Matched Iupac: … benzyl N-[(1S)-4-[(diaminomethyl)amino]-1-{[(2S)-4-fluoro-3-oxobutan-2-yl]carbamoyl}butyl]carbamate …
Matched Iupac: … benzyl N-[(1S)-4-[(diaminomethyl)amino]-1-{[(2S)-4-fluoro-3-oxobutan-2-yl]carbamoyl}butyl]carbamate …
3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid
Experimental
Matched Name: … 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic …
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID
Experimental
Matched Name: … (2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL …
Matched Iupac: … (2S)-2-[3-(aminomethyl)phenyl]-3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-methylpropyl](hydroxy)phosphoryl …
Matched Iupac: … (2S)-2-[3-(aminomethyl)phenyl]-3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-methylpropyl](hydroxy)phosphoryl …
(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID
Experimental
Matched Name: … 2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL …
Matched Iupac: … (2S)-2-[3-(aminomethyl)phenyl]-3-{hydroxy[(1R)-2-methyl-1-(2-phenylethanesulfonamido)propyl]phosphoryl …
Matched Iupac: … (2S)-2-[3-(aminomethyl)phenyl]-3-{hydroxy[(1R)-2-methyl-1-(2-phenylethanesulfonamido)propyl]phosphoryl …
Letrozole
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Approved
Investigational
Matched Description: … ], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. ... [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … LETROZOL AMAROX 2.5MG FTA …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … LETROZOL AMAROX 2.5MG FTA …
Inula helenium root
Inula helenium root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Matched Synonyms: … Wood Fragrance (Inula Helenium) …
5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one
Experimental
Matched Name: … 5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin …
Nebivolol
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta...
Approved
Investigational
Matched Description: … Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other ... [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure ... [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are …
Matched Categories: … Beta blocking agents and calcium channel blockers ... Beta Blocking Agents and Thiazides ... valsartan and nebivolol ... nebivolol and amlodipine ... nebivolol and thiazides …
Matched Products: … NEBIVOLOLO AMAROX …
Matched Categories: … Beta blocking agents and calcium channel blockers ... Beta Blocking Agents and Thiazides ... valsartan and nebivolol ... nebivolol and amlodipine ... nebivolol and thiazides …
Matched Products: … NEBIVOLOLO AMAROX …
(1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]
Experimental
Matched Name: … (1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl …
Matched Iupac: … {[(1R,2S,3R,5S,6R)-2,3,5-trihydroxy-4-{[hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-6-(phosphonooxy …
Matched Iupac: … {[(1R,2S,3R,5S,6R)-2,3,5-trihydroxy-4-{[hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-6-(phosphonooxy …
Allopurinol
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
Allopurinol is a xanthine oxidase enzyme inhibitor that...
Approved
Matched Description: … This disease has been well-documented in historical medical records and appears in the biographies of ... enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and ... It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [ …
Matched Salts name: … Allopurinol sodium …
Matched Products: … Allopurinol sodium …
Matched Salts name: … Allopurinol sodium …
Matched Products: … Allopurinol sodium …
(3,4,8b-Trimethyl-3-oxido-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-3-ium-7-yl) N-(2-ethylphenyl)carbamate
Experimental
Matched Name: … (3,4,8b-Trimethyl-3-oxido-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-3-ium-7-yl) N-(2-ethylphenyl)carbamate …
(2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE
Experimental
Matched Name: … (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E …
(5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one
Experimental
Matched Name: … (5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol …
Etoposide toniribate
Investigational
Matched Synonyms: … 6-oxo-5,5a,6,8,8a,9-hexahydro-2h-furo(3',4':6,7)naphtho(2,3-d)(1,3)dioxol-5-yl)-2,6-dimethoxyphenyl carbonate …
Matched Iupac: … [(10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin ... .0^{11,15}]hexadeca-1(9),2,7-trien-10-yl]-2,6-dimethoxyphenyl (2,2-dimethyl-1,3-dioxolan-4-yl)methyl carbonate …
Matched Iupac: … [(10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin ... .0^{11,15}]hexadeca-1(9),2,7-trien-10-yl]-2,6-dimethoxyphenyl (2,2-dimethyl-1,3-dioxolan-4-yl)methyl carbonate …
(3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
Experimental
Matched Name: … (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE …
4-{4-[2-(1A,7A-DIMETHYL-4-OXY-OCTAHYDRO-1-OXA-4-AZA-CYCLOPROPA[A]NAPHTHALEN-4-YL) -ACETYLAMINO]-PHENYLCARBAMOYL}-BUTYRIC ACID
Experimental
Matched Name: … 4-{4-[2-(1A,7A-DIMETHYL-4-OXY-OCTAHYDRO-1-OXA-4-AZA-CYCLOPROPA[A]NAPHTHALEN-4-YL) -ACETYLAMINO]-PHENYLCARBAMOYL …
Fosgemcitabine palabenamide
NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
Investigational
Matched Synonyms: … 3R,5R)-5-(4-AMINO-2-OXO-PYRIMIDIN-1-YL)-4,4-DIFLUORO-3-HYDROXY-TETRAHYDROFURAN-2-YL)METHOXY-PHENOXY-PHOSPHORYL …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Methyl [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate
Experimental
Matched Name: … [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethyl-2,4-octadienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate …
Matched Iupac: … [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethylocta-2,4-dienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate …
Matched Iupac: … [(1E,5R)-5-{3-[(2E,4E)-2,5-dimethylocta-2,4-dienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate …
Finasteride
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug...
Approved
Matched Description: … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase ... first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and ... [L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo …
Matched Mixtures name: … Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% ... Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025% …
Matched Categories: … doxazosin and finasteride ... alfuzosin and finasteride ... finasteride and tadalafil ... Skin and Mucous Membrane Agents ... Genito Urinary System and Sex Hormones …
Matched Products: … FINASTERIDE AMAROX …
Matched Mixtures name: … Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% ... Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025% …
Matched Categories: … doxazosin and finasteride ... alfuzosin and finasteride ... finasteride and tadalafil ... Skin and Mucous Membrane Agents ... Genito Urinary System and Sex Hormones …
Matched Products: … FINASTERIDE AMAROX …
Displaying drugs 926 - 950 of 976 in total